- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program
- Targeting range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis
- Pyramid Biosciences Inc. will develop and commercialize potential therapies globally
PR Newswire
WALTHAM, Mass., Dec. 17, 2018